Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 20/20 | 0.44 |
| ▸ | PLG | P00747 | 16/20 | 0.44 |
| ▸ | F2 | P00734 | 6/20 | 0.44 |
| ▸ | F10 | P00742 | 6/20 | 0.44 |
| ▸ | ST14 | Q9Y5Y6 | 6/20 | 0.44 |
| ▸ | PLAT | P00750 | 4/20 | 0.40 |
| ▸ | HPN | P05981 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954061 | 0.87 | PLAU (0.52) | PLAUPLGF2F10ST14 | |
| Hydrochloric Acid SCHEMBL250043 | 0.87 | PLAU (0.51) | PLAUPLGF2F10ST14 | |
| SCHEMBL2953288 | 0.85 | PLAU (0.48) | PLAUPLGF2F10ST14 | |
| Hydrochloric Acid SCHEMBL4451933 | 0.85 | PLAU (0.48) | PLAUPLGF2F10ST14 | |
| SCHEMBL7058121 | 0.72 | PLG (0.43) | PLAUPLGF2F10ST14 | |
| SCHEMBL5309785 | 0.70 | PLAU (0.37) | PLAUPLGF2F10ST14 | |
| SCHEMBL6551292 | 0.66 | MGLL (0.30) | — | |
| SCHEMBL4557533 | 0.66 | PLG (0.48) | PLAUPLGF2F10ST14 | |
| Hydrochloric Acid SCHEMBL7587516 | 0.66 | KMT2A (0.46) | — | |
| Hydrochloric Acid SCHEMBL4458403 | 0.65 | PLG (0.47) | PLAUPLGF2F10ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342018-B2 | Urokinase inhibitors and uses thereof | WILEX AG (DE) | 2008-03-11 | — | — | US | disclosed |
| EP-1480963-B1 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| US-20040138233-A1 | Novel urokinase inhibitors | WILEX AG (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1264828-B1 | Inhibitor of urokinase | WILEX AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-6680320-B2 | ANTITUMOR AGENTS | WILEX AG (DE) | 2004-01-20 | — | — | US | disclosed |
| US-6624169-B1 | 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases targeting lymphocytes and for treating disorders of the lymphatic tissue, in particular lymphomas. | WILEX BIOTECHNOLOGY GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030013723-A1 | Antitumor agents | WILEX AG | 2003-01-16 | — | — | US | disclosed |
| EP-1098651-B1 | NOVEL UROKINASE INHIBITORS | WILEX AG (DE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1264828-A1 | New inhibitor of urokinase | Wilex AG (DE) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138233-A1 | Novel urokinase inhibitors | PLAU, PLAUR, DNPEP | PLAU 1/4885PLG 22/4885F2 684/4885 |
| US-20030013723-A1 | Antitumor agents | DNPEP, PLAU, ENPEP | PLAU 2/4885PLG 50/4885F2 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.